What do systematic reviews say?

Meropenem vs usual care

It is very uncertain whether meropenem changes all‐cause mortality maximum compared with standard care (very low certainty).

• Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
  RR 1.42 [0.56, 3.62]
  1 study · 271 participants
  Very low

Pre‐emptive antifungal therapy vs empirical antifungal therapy

Pre‐emptive antifungal therapy showed no clear difference in all‐cause mortality compared with empirical antifungal therapy (low certainty).

• Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer 2022 · Cochrane Headline outcomes only
  RR 0.97 [0.72, 1.3]
  6 studies · 1459 participants
  Low

NPWT vs the Bogota bag

It is very uncertain whether NPWT changes all‐cause mortality compared with the Bogota bag (very low certainty).

• Negative pressure wound therapy for managing the open abdomen in non‐trauma patients 2022 · Cochrane Headline outcomes only
  RR 0.71 [0.27, 1.88]
  1 study · 40 participants
  Very low

Suprasorb CNP system vs the ABThera system

It is very uncertain whether suprasorb CNP system changes all‐cause mortality compared with the ABThera system (very low certainty).

• Negative pressure wound therapy for managing the open abdomen in non‐trauma patients 2022 · Cochrane Headline outcomes only
  RR 0.33 [0.04, 2.89]
  1 study · 34 participants
  Very low

Intervention not reported

The intervention showed no clear difference in all‐cause mortality (low certainty).

• Thrombopoietin receptor agonists for prevention and treatment of chemotherapy‐induced thrombocytopenia in patients… 2017 · Cochrane Headline outcomes only
  RR 1.35 [0.53, 3.45]
  1 study · 26 participants
  Low

Untargeted antifungal treatment with any antifungal drug (systemic or nonabsorbable) vs Placebo, no treatment, or another active antifungal intervention

Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in total (all‐cause) mortality compared with placebo/no antifungal/any other antifungal (moderate certainty).

• Antifungal agents for preventing fungal infections in non‐neutropenic critically ill patients 2016 · Cochrane Headline outcomes only
  RR 0.93 [0.79, 1.09]
  19 studies · 2374 participants
  Moderate

Intervention not reported

It is very uncertain whether the intervention changes all‐cause mortality up to 30 days (very low certainty).

• Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction 2015 · Cochrane Headline outcomes only
  RR 0.92 [0.63, 1.36]
  7 studies · 437 participants
  Very low

Pine bark extract vs control

The review found no eligible studies for this question.

• Pine bark (Pinus spp.) extract for treating chronic disorders 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pathogen‐reduced platelets vs standard platelets

Pathogen‐reduced platelets showed no clear difference in all‐cause mortality compared with standard platelets (moderate certainty).

• Pathogen‐reduced platelets for the prevention of bleeding 2017 · Cochrane Headline outcomes only
  RR 0.81 [0.5, 1.29]
  6 studies · 1509 participants
  Moderate

Summary of findings table ‐ Platelet transfusion vs no platelet transfusion

The review found no eligible studies for this question.

• Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Thrombopoietin mimetics vs placebo

It is very uncertain whether thrombopoietin mimetic changes all‐cause mortality compared with placebo (very low certainty).

• Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to… 2016 · Cochrane Headline outcomes only
  RR 0.74 [0.52, 1.05]
  5 studies · 456 participants
  Very low

Tranexamic acid vs placebo

• Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 100 participants
  Very low

Summary of findings: Fibrin sealant vs usual care

It is very uncertain whether summary of findings: Fibrin sealant changes all‐cause mortality up to 30 days compared with usual care (very low certainty).

• Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and… 2023 · Cochrane Headline outcomes only
  RR 0.44 [0.11, 1.76]
  3 studies · 585 participants
  Very low

Pulmonary artery perfusion with blood vs no perfusion during cardiopulmonary bypass

It is very uncertain whether pulmonary artery perfusion with blood changes all‐cause mortality within longest compared with no perfusion during cardiopulmonary bypass (very low certainty).

• Pulmonary artery perfusion versus no perfusion during cardiopulmonary bypass for open heart surgery in adults 2018 · Cochrane Headline outcomes only
  Peto OR 1.78 [0.43, 7.4]
  4 studies · 210 participants
  Very low